Because the drugs identified are already FDA-approved, many insurers will cover them, especially with the Scientific Evidence Report Cancer Commons provides. Prior authorization, compassionate use programs, and other payment pathways are explored for each patient. The study team works with you and your oncologist to navigate coverage.